Catecholamine metabolism: A contemporary view with implications for physiology and medicine

Pharmacological Reviews

Volumn 56, Issue 3, 2004, Pages 331-349

  Eisenhofer, Graeme ^a,b   Kopin, Irwin J ^a   Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYMANDELIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ALDEHYDE; ALDEHYDE DEHYDROGENASE; AMINE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; NORADRENALIN; VANILMANDELIC ACID; VESICULAR ACETYLCHOLINE TRANSPORTER;

ACTIVE TRANSPORT; CATALYSIS; CATECHOLAMINE METABOLISM; CATECHOLAMINE NERVE CELL; DEAMINATION; DOPAMINE METABOLISM; HORMONAL REGULATION; MEDICINE; METHYLATION; MONOAMINE RELEASE; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; PHEOCHROMOCYTOMA; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPATHETIC NERVE;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CATECHOLAMINES; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE;

EID: 4143144205     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.56.3.1     Document Type: Review

References (223)

1. Akiyama T and Yamazaki T (2001) Myocardial interstitial norepinephrine and dihydroxyphenylglycol levels during ischemia and reperfusion. Cardiovasc Res 49:78-85.
2. Åneman A, Eisenhofer G, Fandriks L, and Friberg P (1995) Hepatomesenteric release and removal of norepinephrine in swine. Am J Physiol 268:R924-R930.
3. Åneman A, Eisenhofer G, Olbe L, Dalenback J, Nitescu P, Fandriks L, and Friberg P (1996) Sympathetic discharge to mesenteric organs and the liver. Evidence for substantial mesenteric organ norepinephrine spillover. J Clin Investig 97:1640-1646.
4. Änggård E, Lewander T, and Sjöquist B (1974) Determination of homovanillic acid turnover in man. Life Sci 15:111-122.
5. Armstrong MD, McMillan A, and Shaw KN (1957) 3-Methoxy-4-hydroxy-D- mandelic acid, a urinary metabolite of norepinephrine. Biochim Biophys Acta 25:422-423.
6. Armstrong MD and McMillan S (1959) Studies on the formation of 3-methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine and epinephrine. Pharmacol Rev 11:394-401.
7. Axelrod J, Kopin IJ, and Mann JD (1959) 3-Methoxy-4-hydroxyphenylglycol sulfate, a new metabolite of epinephrine and norepinephrine. Biochim Biophys Acta 36: 576-577.
8. Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strasser RH, Kubler W, and Haass M (2001) The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 33:461-472.
9. Beau SL and Saffitz JE (1994) Transmural heterogeneity of norepinephrine uptake in failing human hearts. J Am Coll Cardiol 23:579-585.
10. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT (2002) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
11. Bianchi P, Seguelas MH, Parini A, and Cambon C (2003) Activation of Pro-Apoptotic Cascade by Dopamine in Renal Epithelial Cells is Fully Dependent on Hydrogen Peroxide Generation by Monoamine Oxidases. J Am Soc Nephrol 14:855-862.
12. Blaschko H (1952) Amine oxidase and amine metabolism. Pharmacol Rev 4:415-453.
13. Blombery PA, Kopin IJ, Gordon EK, Markey SP, and Ebert MH (1980) Conversion of MHPG to vanillylmandelic acid. Implications for the importance of urinary MHPG. Arch Gen Psychiatry 37:1095-1098.
14. Bohm M, La Rosee K, Schwinger RH, and Erdmann E (1995) Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25:146-153.
15. Boobis AR, Murray S, Jones DH, Reid JL, and Davies DS (1980) Urinary conjugates of 4-hydroxy-3-methoxyphenylethylene glycol do not provide an index of brain amine turnover in man. Clin Sci 58:311-316.
16. Breese GR, Chase TN, and Kopin IJ (1969) Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain. J Pharmacol Exp Ther 165:9-13.
17. Brodie BB, Costa E, Dlabac A, Neff NH, and Smookler HH (1966) Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines. J Pharmacol Exp Ther 154:493-498.
18. Brown M (1984) Simultaneous assay of noradrenaline and its deaminated metabolite, dihydroxyphenylglycol, in plasma: a simplified approach to the exclusion of pheochromocytoma in patients with borderline elevation of plasma noradrenaline concentration. Eur J Clin Investig 14:67-72.
19. Burke RE, Macaya A, DeVivo D, Kenyon N, and Janec EM (1992) Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons. Neuroscience 50:559-569.
20. Burke WJ, Li SW, Zahm DS, Macarthur H, Kolo LL, Westfall TC, Anwar M, Glickstein SB, and Ruggiero DA (2001) Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res 891:218-227.
21. Burke WJ, Schmitt CA, Gillespie KN, and Li SW (1996) Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Brain Res 722:232-235.
22. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797-8807.
23. Chahine R, Nadeau R, Lamontagne D, Yamaguchi N, and de Champlain J (1994) Norepinephrine and dihydroxyphenylglycol effluxes from sympathetic nerve endings during hypoxia and reoxygenation in the isolated rat heart. Can J Physiol Pharmacol 72:595-601.
24. Chidsey CA and Braunwald E (1966) Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev 18:685-700.
25. Christensen T, Bruhn T, Balchen T, and Diemer NH (1994) Evidence for formation of hydroxyl radicals during reperfusion after global cerebral ischaemia in rats using salicylate trapping and microdialysis. Neurobiol Dis 1:131-138.
26. Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19:89-103.
27. Crout JR, Pisano JJ, and Sjoerdsma A (1961) Urinary excretion of catecholamines and their metabolites in pheochromocytoma. Am Heart J 61:375-381.
28. Crout JR and Sjoerdsma A (1964) Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Investig 43:94-102.
29. Dajani R, Cleasby A, Neu M, Wonacott AJ, Jhoti H, Hood AM, Modi S, Hersey A, Taskinen J, Cooke RM, et al. (1999) X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity. J Biol Chem 274:37862-37868.
30. Dajani R, Hood AM, and Coughtrie MW (1998) A single amino acid, glu146, governs the substrate specificity of a human dopamine sulfotransferase, SULT1A3. Mol Pharmacol 54:942-948.
31. Damsma G, Boisvert DP, Mudrick LA, Wenkstern D, and Fibiger HC (1990) Effects of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin and their metabolites in the rat striatum as determined by in vivo microdialysis. J Neurochem 54:801-808.
32. Davidson L, Vandongen R, and Beilin LJ (1981) Effects of eating bananas on plasma free and sulfate-conjugated catecholamines. Life Sci 29:1773-1778.
33. Davis VE, Brown H, Huff JA, and Cashaw JL (1967a) The alteration of serotonin metabolism to 5-hydroxytryptophol by ethanol ingestion in man. J Lab Clin Med 69:132-140.
34. Davis VE, Brown H, Huff JA, and Cashaw JL (1967b) Ethanol-induced alterations of norepinephrine metabolism in man. J Lab Clin Med 69:787-799.
35. DeMet EM and Halaris AE (1979) Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids. Biochem Pharmacol 28:3043-3050.
36. Denis P, Nordmann JP, Elena PP, Dussaillant M, Saraux H, and Lapalus P (1993) Physiological roles of dopamine and neuropeptides in the retina. Fund Clin Pharmacol 7:293-304.
37. DeQuattro V, Nagatsu T, Mendez A, and Verska J (1973) Determinants of cardiac noradrenaline depletion in human congestive failure. Cardiovasc Res 7:344-350.
38. DeQuattro V, Sullivan P, Foti A, Bornheimer J, Schoentgen S, Versales G, Levine D, and Kobayashi K (1980) Central and regional normetadrenaline in evaluation of neurogenic aspects of hypertension: aid to diagnosis of phaeochromocytoma. Clin Sci 59:275s-277s.
39. Djamgoz MB, Hankins MW, Hirano J, and Archer SN (1997) Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res 37:3509-3529.
40. Dong WX and Ni XL (2002) Norepinephrine metabolism in neuron: dissociation between 3,4-dihydroxyphenylglycol and 3,4-dihydroxymandelic acid pathways. Acta Pharmacol Sin 23:59-65.
41. Duncan MW, Compton P, Lazarus L, and Smythe GA (1988) Measurement of norepinephrine and 3,4-dihydroxyphenylglycol in urine and plasma for the diagnosis of pheochromocytoma. N Engl J Med 319:136-142.
42. Duncan RJ and Sourkes TL (1974) Some enzymic aspects of the production of oxidized or reduced metabolites of catecholamines and 5-hydroxytryptamine by brain tissues. J Neurochem 22:663-669.
43. Edwards LL, Quigley EM, and Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42:726-732.
44. Eisenhofer G (1994) Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. Naunyn Schmiedebergs Arch Pharmacol 349:259-269.
45. Eisenhofer G (2001) The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62.
46. Eisenhofer G, Åneman A, Friberg P, Hooper D, Fandriks L, Lonroth H, Hunyady B, and Mezey E (1997) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82:3864-3871.
47. Eisenhofer G, Åneman A, Hooper D, Holmes C, Goldstein DS, and Friberg P (1995a) Production and metabolism of dopamine and norepinephrine in mesenteric organs and liver of swine. Am J Physiol 268:G641-G649.
48. Eisenhofer G, Åneman A, Hooper D, Rundqvist B, and Friberg P (1996a) Mesenteric organ production, hepatic metabolism and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 66:1565-1573.
49. Eisenhofer G, Coughtrie MW, and Goldstein DS (1999a) Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol 26:S41-S53.
50. Eisenhofer G, Cox HS, and Esler MD (1990) Parallel increases in noradrenaline reuptake and release into plasma during activation of the sympathetic nervous system in rabbits. Naunyn-Schmiedebergs Arch Pharmacol 342:328-335.
51. Eisenhofer G, Cox HS, and Esler MD (1991a) Noradrenaline reuptake and plasma dihydroxyphenylglycol during sustained changes in sympathetic activity in rabbits. J Auton Nerv Sys 32:217-232.
52. Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO, Quyyumi AA, Lambert G, Chin J, Jennings GL, and Goldstein DS (1992a) Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 85:1775-1785.
53. Eisenhofer G, Esler MD, Meredith IT, Ferrier C, Lambert G, and Jennings G (1991b) Neuronal re-uptake of noradrenaline by sympathetic nerves in humans. Clin Sci 80:257-263.
54. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, Quyyumi AA, Brunner HG, and Lenders JW (1995b) Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamuie metabolism? Clin Sci 88:533-542.
55. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, and Esler MD (1996b) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93:1667-1676.
56. Eisenhofer G, Goldstein DS, Ropchak TG, Nguyen HQ, Keiser HR, and Kopin IJ (1988a) Source and physiological significance of plasma 3,4- dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. J Anton Nerv Syst 24:1-14.
57. Eisenhofer G, Goldstein DS, Stall R, Ropchak TG, Keiser HR, and Kopin IJ (1987) Dihydroxyphenylglycol and dihydroxymandelic acid during intravenous infusions of noradrenaline. Clin Sci 73:123-125.
58. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JWM, Keiser HR, and Pacak K (2003) Biochemical diagnosis of pheochromocytoma: How to distinguish true- from false-positive test results. J Clin Endocrinol Metab 88:2656-2666.
59. Eisenhofer G, Huynh T-T, Hiroi M, and Pacak K (2001) Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Rev Endocr Metab Dis 2:297-311.
60. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, and Lenders JW (1998a) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O- methyltransferase within tumors. J Clin Endocrinol Metab 83:2175-2185.
61. Eisenhofer G, Lamensdorf I, Kirk KL, Kawamura M, and Sato S (2000) Oxidative deamination of monoamines and biogenic aldehydes in neurodegeneration, in Role of Quinone Species in Cellular Toxicity (Creveling CR ed), pp. 103-145, F.P. Graham, Johnson City, TN.
62. Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, and Keiser HR (1999b) Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340:1872-1879.
63. Eisenhofer G, Meredith IT, Ferrier C, Cox HS, Lambert G, Jennings GL, and Esler MD (1991c) Increased plasma dihydroxyphenylalanine during sympathetic activation in humans is related to increased norepinephrine turnover. J Lab Clin Med 117:266-273.
64. Eisenhofer G, Pecorella W, Pacak K, Hooper D, Kopin IJ, and Goldstein DS (1994) The neuronal and extraneuronal origins of plasma 3-methoxy-4- hydroxyphenylglycol in rats. J Auton Nerv Syst 50:93-107.
65. Eisenhofer G, Ropchak TG, Kopin IJ, and Goldstein DS (1988b) Release, metabolism and intraneuronal disposition of exogenous, endogenous and newly synthesized norepinephrine in the rat vas deferens. J Pharmacol Exp Ther 245:81-88.
66. Eisenhofer G, Rundqvist B, Aneman A, Friberg P, Dakak N, Kopin IJ, Jacobs MC, and Lenders JW (1995c) Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. J Clin Endocrinol Metab 80:3009-3017.
67. Eisenhofer G, Rundqvist B, and Friberg P (1998b) Determinants of cardiac tyrosine hydroxylase activity during exercise-induced sympathetic activation in humans. Am J Physiol 43:R626-R634.
68. Eisenhofer G, Smolich JJ, Cox HS, and Esler MD (1991d) Neuronal reuptake of norepinephrine and production of dihydroxyphenylglycol by cardiac sympathetic nerves in the anesthetized dog. Circulation 84:1354-1363.
69. Eisenhofer G, Smolich JJ, and Esler MD (1992b) Increased cardiac production of dihydroxyphenylalanine (DOPA) during sympathetic stimulation in anaesthetized dogs. Neurochem Int 21:37-44.
70. Elchisak MA, Polinsky RJ, Ebert MH, and Kopin IJ (1982) Kinetics of homovanillic acid and determination of its production rate in humans. J Neurochem 38:380-385.
71. Eldrup E, Moller SE, Andreasen J, and Christensen NJ (1997) Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid. Clin Sci 92:423-430.
72. Ellingson T, Duddempudi S, Greenberg BD, Hooper D, and Eisenhofer G (1999) Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. J Chromatogr B 729:347-353.
73. Elsworth JD, Redmond DE Jr, and Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 235:115-124.
74. Eriksson BM and Persson BA (1987) Liquid Chromatographic method for the determination of 3,4-dihydroxyphenylethylene glycol and 3,4-dihydroxymandelic acid in plasma. J Chromatogr 386:1-9.
75. Erwin VG and Deitrich RA (1966) Brain aldehyde dehydrogenase. Localization, purification and properties. J Biol Chem 241:3533-3539.
76. Filloux F and Townsend JJ (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119:79-88.
77. Filser JG, Spira J, Fischer M, Gattaz WF, and Muller WE (1988) The evaluation of 4-hydroxy-3-methoxyphenylglycol sulfate as a possible marker of central norepinephrine turnover. Studies in healthy volunteers and depressed patients. J Psychiatry Res 22:171-181.
78. Finkel Y, Eklof AC, Granquist L, Soares-da-Silva P, and Bertorello AM (1994) Endogenous dopamine modulates jejunal sodium absorption during high-salt diet in young but not in adult rats. Gastroenterology 107:675-679.
79. Flaherty JT and Weisfeldt ML (1988) Reperfusion injury. Free Rad Biol Med 5:409-419.
80. Flemstrom G and Safsten B (1994) Role of dopamine and other stimuli of mucosal bicarbonate secretion in duodenal protection. Dig Dis Sci 39:1839-1842.
81. Floor E, Leventhal PS, Wang Y, Meng L, and Chen W (1995) Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J Neurochem 64:689-699.
82. Fried G (1981) Noradrenaline release and uptake in isolated small dense cored vesicles from rat seminal ducts. Acta Physiol Scand 112:41-46.
83. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, and Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19:2424-2431.
84. Gerlo EA and Sevens C (1994) Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. Clin Chem 40:250-256.
85. Glavin GB and Hall AM (1995) Central and peripheral dopamine D1/DA1 receptor modulation of gastric secretion and experimental gastric mucosal injury. Gen Pharmacol 26:1277-1279.
86. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, and Kopin IJ (1988) Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Investig 81:213-220.
87. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, and Cannon RO (2000) Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133:338-347.
88. Goldstein DS, Holmes CS, Dendi R, Bruce SR, and Li ST (2002) Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58:1247-1255.
89. Goldstein DS, Li ST, and Kopin IJ (2001) Sympathetic neurocirculatory failure in Parkinson disease: evidence for an etiologic role of alpha-synuclein. Ann Intern Med 135:1010-1011.
90. Goldstein DS, Mezey E, Yamamoto T, Aneman A, Friberg P, and Eisenhofer G (1995) Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Hypertens Res 18:S93-S99.
91. Goldstein DS, Swoboda KJ, Miles JM, Coppack SW, Aneman A, Holmes C, Lamensdorf I, and Eisenhofer G (1999) Sources and physiological significance of plasma dopamine sulfate. J Clin Endocrinol Metab 84:2523-2531.
92. Goodall M (1959) Metabolic products of adrenaline and noradrenaline in human urine. Pharmacol Rev 11:416-425.
93. Goodall M and Alton H (1969) Metabolism in the human of 3,4-dihydroxymandelic acid, one of the metabolites of noradrenaline and adrenaline. Biochem Pharmacol 18:295-302.
94. Gordon K, Statman D, Johnston MV, Robinson TE, Becker JB, and Silverstein FS (1990) Transient hypoxia alters striatal catecholamine metabolism in immature brain: an in vivo microdialysis study. J Neurochem 54:605-611.
95. Graefe KH and Henseling M (1983) Neuronal and extraneuronal uptake and metabolism of catecholamines. Gen Pharmacol 14:27-33.
96. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
97. Graham DG, Tiffany SM, Bell WR Jr, and Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653.
98. Halbrügge T, Wolfel R, and Graefe KH (1989) Plasma 3,4-dihydroxyphenylglycol as a tool to assess the role of neuronal uptake in the anaesthetized rabbit. Naunyn-Schmiedebergs Arch Pharmacol 340:726-732.
99. Harnois C and Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson's disease. Investig Ophthalmol Vis Sci 31:2473-2475.
100. Haskel Y and Hanani M (1994) Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms. Dig Dis Sci 39:2364-2367.
101. Hastings TG, Lewis DA, and Zigmond MJ (1996a) Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol 387: 97-106.
102. Hastings TG, Lewis DA, and Zigmond MJ (1996b) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 93:1956-1961.
103. Henry JP, Sagne C, Bedet C, and Gasnier B (1998) The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem Int 32:227-246.
104. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, and Liang CS (1993) Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 88:1299-1309.
105. Hoeldtke RD and Wurtman RJ (1974) Cereal ingestion and catecholamine excretion. Metabolism 23:33-41.
106. Howes LG and Reid JL (1985) Changes in plasma free 3,4- dihydroxyphenylethylene glycol and noradrenaline levels after acute alcohol administration. Clin Sci 69: 423-428.
107. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, and Fukuyama T (1995) Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 26:1594-1599.
108. Izzo JL Jr, Thompson DA, and Honvitz D (1985) Plasma dihydroxyphenylglycol (DHPG) in the in vivo assessment of human neuronal norepinephrine metabolism. Life Sci 37:1033-1038.
109. Jaber M, Dumartin B, Sagne C, Haycock JW, Roubert C, Giros B, Bloch B, and Caron MG (1999) Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur J Neurosci 11:3499-3511.
110. Jewett SL, Eddy LJ, and Hochstein P (1989) Is the autoxidation of catecholamines involved in ischemia-reperfusion injury? Free Rad Biol Med 6:185-188.
111. Johnston MV (1983) Neurotransmitter alterations in a model of perinatal hypoxic-ischemic brain injury. Ann Neurol 13:511-518.
112. Johnston MV, Silverstein F, and Hassett K (1984) Impact of perinatal hypoxia-ischemia on developing neurotransmitter systems. Int J Neurol 18:151-162.
113. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, and Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
114. Kanthasamy AG, Borowitz JL, Pavlakovic G, and Isom GE (1994) Dopaminergic neurotoxicity of cyanide: neurochemical, histological and behavioral characterization. Toxicol Appl Pharmacol 126:156-163.
115. Karoum F, Moyer-Schwing J, Potkin SG, and Wyatt RJ (1977) Presence of free, sulfate and glucuronide conjugated 3-methoxy-4-hydroxyphenylglycol (MHPG) in human brain, cerebrospinal fluid and plasma. Brain Res 125:333-339.
116. Kawamura M, Eisenhofer G, Kopin IJ, Kador P, Lee YS, Fujisawa S, and Sato S (2002) Aldose reductase: an aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia. Auton Neurosci 96:131-139.
117. Kawamura M, Eisenhofer G, Kopin IJ, Kador PF, Lee YS, Tsai JY, Fujisawa S, Lizak MJ, Sinz A, and Sato S (1999) Aldose reductase, a key enzyme in the oxidative deamination of norepinephrine in rats. Biochem Pharmacol 58:517-524.
118. Kawamura M, Kopin IJ, Kador PF, Sato S, Tjurmina O, and Eisenhofer G (1997) Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J Auton Nerv Syst 66:145-148.
119. Kilbourn MR, Sherman P, and Abbott LC (1998) Reduced MPTP neurotoxicity in striatum of the mutant mouse tottering. Synapse 30:205-210.
120. Kopin IJ (1964) Storage and metabolism of catecholamines: the role of monoamine oxidase. Pharmacol Rev 16:179-191.
121. Kopin IJ (1982) Evolving views of the metabolic fate of norepinephrine. Endocrinol Exp 16:291-300.
122. Kopin IJ (1985) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37:333-364.
123. Kopin IJ and Axelrod J (1960) Presence of 3-methoxy-4-hydroxyphenylglycol and metanephrine in phaechromocytoma tissue. Nature (Lond) 185:788.
124. Kopin IJ, Blombery P, Ebert MH, Gordon EK, Jimerson D, Markey SP, and Polinsky RJ (1984a) Disposition and metabolism of MHPG-CD3 in humans: plasma MHPG as the principal pathway of norepinephrine metabolism and as an important determinant of CSF levels of MHPG., in Frontiers in Biochemical and Pharmacological Research in Depression (Usdin E ed), pp. 57-68, Raven Press, New York.
125. Kopin IJ, Blombery P, Ebert MH, Gordon EK, Jimerson DC, Markey SP, and Polinsky RJ (1984b) Disposition and metabolism of MHPG-CD3 in humans: plasma MHPG as the principal pathway of norepinephrine metabolism and as an important determinant of CSF levels of MHPG. Adv Biochem Psychopharmacol 39:57-68.
126. 3 released by tyramine and reserpine. J Pharmacol Exp Ther 138:351-358.
127. Kopin IJ, Gordon EK, Jimerson DC, and Polinsky RJ (1983) Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science (Wash DC) 219:73-75.
128. Kopin IJ, Jimerson DC, Markey SP, Ebert MH, and Polinsky RJ (1984c) Disposition and metabolism of MHPG in humans: application to studies in depression. Pharmacopsychiatry 17:3-8.
129. Kumagae Y, Matsui Y, and Iwata N (1990) Participation of type A monoamine oxidase in the activated deamination of brain monoamines shortly after reperfusion in rats. Jpn J Pharmacol 54:407-413.
130. Kunduzova OR, Bianchi P, Parini A, and Cambon C (2002) Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion. Eur J Pharmacol 448:225-230.
131. Kuroda S and Siesjo BK (1997) Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Clin Neurosci 4:199-212.
132. LaBrosse EH (1970) Catecholamine metabolism in neuroblastoma: kinetics of conversion of 3H-3-methoxy-4-hydroxyphenylglycol to 3H-3-methoxy-4- hydroxymandelic acid. J Clin Endocrinol Metab 30:580-589.
133. LaBrosse EH, Comoy E, Bohuon C, Zucker JM, and Schweisguth O (1976) Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst 57:633-638.
134. Lambert GW, Eisenhofer G, Cox HS, Home M, Kalff V, Kelly M, Jennings GL, and Esler MD (1991) Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity. Life Sci 49:1061-1072.
135. Lambert GW, Eisenhofer G, Jennings GL, and Esler MD (1993) Regional homovanillic acid production in humans. Life Sci 53:63-75.
136. Lambert GW, Kaye DM, Vaz M, Cox HS, Turner AG, Jennings GL, and Esler MD (1995) Regional origins of 3-methoxy-4-hydroxyphenylglycol in plasma: effects of chronic sympathetic nervous activation and denervation and acute reflex sympathetic stimulation. J Auton Nerv Syst 55:169-178.
137. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, and Kopin IJ (2000a) Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res 60: 552-558.
138. Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, and Kopin IJ (2000b) 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 868:191-201.
139. Lamontagne D, Yamaguchi N, Ribuot C, de Champlain J, and Nadeau R (1991) Reduction of tissue noradrenaline content in the isolated perfused rat heart during ischemia: importance of monoamine oxidation. Can J Physiol Pharmacol 69:1190-1195.
140. Lee MR (1993) Dopamine and the kidney: ten years on. Clin Sci 84:357-375.
141. Leeper LC, Weissbach H, and Udenfriend S (1958) Studies on the metabolism of norepinephrine, epinephrine and their O-methyl analogs by partially purified enzyme preparations. Arch Biochem Biophys 77:417-427.
142. Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, and Mark AL (1986) Direct evidence from intraneuronal recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73:913-919.
143. Lenders JW, Eisenhofer G, Armando I, Keiser HR, Goldstein DS, and Kopin IJ (1993) Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem 39:97-103.
144. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, and Eisenhofer G (1995) Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 123:101-109.
145. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, and Eisenhofer G (2002) Biochemical diagnosis of pheochromocytoma: which test is best? J Am Med Assoc 287:1427-1434.
146. Lenders JWM, Willemsen JJ, Beissel T, Kloppenborg PWC, Thien T, and Benrad TJ (1992) Value of the plasma norepinephrine/3,4-dihydroxyphenylglycol ratio for the diagnosis of pheochromoctyoma. Am J Med 92:147-152.
147. Li SW, Lin TS, Minteer S, and Burke WJ (2001) 3,4- Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain Res Mol Brain Res 93:1-7.
148. Liang CS, Fan TH, Sullebarger JT, and Sakamoto S (1989) Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamber-specific contributor to beta-adrenoceptor downregulation. J Clin Investig 84:1267-1275.
149. Liu L, Xu W, Harrington KA, and Emson PC (1994) The molecular cloning and expression of a human synaptic vesicle amine transporter that suppresses MPP+ toxicity. Brain Res Mol Brain Res 25:90-96.
150. Liu Y, Peter D, Roghani A, Shuldiner S, Prive GG, Eisenberg D, Brecha N, and Edwards RH (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70:539-551.
151. Lotharius J and Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11:2395-2407.
152. Maas JW, Benensohn H, and Landis DH (1970) A kinetic study of the disposition of circulating norepinephrine in normal male subjects. J Pharmacol Exp Ther 174: 381-387.
153. Maas JW, Hattox SE, Greene NM, and Landis DH (1979) 3-Methoxy- 4hydroxyphenethyleneglycol production by human brain in vivo. Science (Wash DC) 205:1025-1027.
154. Mannelli M, Ianni L, Cilotti A, and Conti A (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619-624.
155. Mårdh G and Änggård E (1984) Norepinephrine metabolism in man using deuterium labelling: origin of 4-hydroxy-3-methoxymandelic acid. J Neurochem 42:43-46.
156. Mårdh G, Luehr CA, and Vallee BL (1985) Human class I alcohol dehydrogenases catalyze the oxidation of glycols in the metabolism of norepinephrine. Proc Natl Acad Sci USA 82:4979-4982.
157. Mårdh G, Sjöquist B, and Änggård E (1983) Norepinephrine metabolism in humans studied by deuterium labelling: turnover of 4-hydroxy-3-methoxyphenylglycol. J Neurochem 41:246-250.
158. Masserano JM, Gong L, Kulaga H, Baker I, and Wyatt RJ (1996) Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 50:1309-1315.
159. Matsui Y and Kumagae Y (1991) Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci Lett 126:175-178.
160. Mattammal MB, Haring JH, Chung HD, Raghu G, and Strong R (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 4:271-281.
161. Merlet P, Pouillart F, Dubois-Rande JL, Delahaye N, Fumey R, Castaigne A, and Syrota A (1999) Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 40:224-231.
162. Mezey E, Eisenhofer G, Hansson S, Harta G, Hoffman BJ, Gallatz K, Palkovits M, and Hunyady B (1999) Non-neuronal dopamine in the gastrointestinal system. Clin Exp Pharmacol Physiol 26:S14-S22.
163. Mezey E, Eisenhofer G, Hansson S, Hunyady B, and Hoffman BJ (1998) Dopamine produced by the stomach may act as a paracrine/autocrine hormone in the rat. Neuroendocrinology 67:336-348.
164. Mezey E, Eisenhofer G, Harta G, Hansson S, Gould L, Hunyady B, and Hoffinan BJ (1996) A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine. Proc Natl Acad Sci USA 93:10377-10382.
165. Michel PP and Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26:428-435.
166. Miller GW, Gainetdinov RR, Levey AI, and Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429.
167. Montanari R, Costa A, and Beavan MA (1963) Turnover rates of norepinephrine in hearts of mice, rats and guinea pigs using tritiated norepinephrine. Life Sci 2:232-240.
168. Moser A, Scholz J, Nobbe F, Vieregge P, Bohme V, and Bamberg H (1995) Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. J Neurol Sci 131:183-189.
169. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res 29:99-111.
170. Nagatsu T and Yoshida M (1988) An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 87:178-182.
171. Naoi M, Dosiert P, Yoshida M, and Nagatsu T (1993) N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv Neurol 60:212-217.
172. Nightingale S, Mitchell KW, and Howe JW (1986) Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects. J Neurol Neurosurg Psychiatry 49:1280-1287.
173. Offen D, Ziv I, Sternin H, Melamed E, and Hochman A (1996) Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 141:32-39.
174. Oo TF, Henchcliffe C, and Burke RE (1995) Apoptosis in substantia nigra following developmental hypoxic-ischemic injury. Neuroscience 69:893-901.
175. Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, and Eisenhofer G (2001) A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab 86:3641-3646.
176. Peaston RT and Lai LC (1993) Biochemical detection of phaeochromocytoma: should we still be measuring urinary HMMA? J Clin Pathol 46:734-737.
177. Peyrin L (1990) Urinary MHPG sulfate as a marker of central norepinephrine metabolism: a commentary. J Neural Trans 80:51-65.
178. Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Ring WS, Goldenberg IF, Reynolds S, and Cohn JN (1987) Heterogeneous myocardial catecholamine concentrations in patients with congestive heart failure. Am J Cardiol 60:316-321.
179. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (Wash DC) 276:2045-2047.
180. Pool PE, Covell JW, Levitt M, Gibb J, and Braunwald E (1967) Reduction of cardiac tyrosine hydroxylase activity in experimental congestive heart failure. Circ Res 20049-353.
181. Port JD, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Murray J, and Bristow MR (1990) Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation 81:929-938.
182. Price MJ, Feldman RG, Adelberg D, and Kayne H (1992) Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 42:887-890.
183. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W, and Roden M (2000) Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Int Med 160:2957-2963.
184. Richter D (1937) Adrenaline and amine oxidase. Biochem J 31:2022-2028.
185. Richter D (1940) The inactivation of adrenaline in vivo in man. J Physiol 98:361-374.
186. Rosenberg PA (1988) Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8:2887-2894.
187. Roth JA (1992) Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the Catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol 120:1-29.
188. Rubin GL, Sharp S, Jones AL, Glatt H, Mills JA, and Coughtrie MW (1996) Design, production and characterization of antibodies discriminating between the phenol- and monoamine-sulphating forms of human phenol sulphotransferase. Xenobiotica 26:1113-1119.
189. Rumantir MS, Kaye DM, Jennings GL, Vaz M, Hastings JA, and Esler MD (2000) Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. Hypertension 36:824-829.
190. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, and Friberg P (1997) Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 95:169-175.
191. Sato T and DeQuattro V (1969) Enzymatic assay for 3,4-dihydroxymandelic acid (DOMA) in human urine, plasma and tissues. J Lab Clin Med 74:672-681.
192. Sawka AM, Jaeschke R, Singh RJ, and Young WF Jr (2003) A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553-558.
193. Schanberg SM, Breese GR, Schildkraut KK, Gordon EK, and Kopin IJ (1968) 3-methoxy-4-hydroxyphenylglycol sulfate in brain and cerebrospinal fluid. Biochem Pharmacol 17:2006-2008.
194. Schömig A, Fischer S, Kurz T, Richardt G, and Schömig E (1987) Nonexocytotic release of endogenous noradrenaline in the ischemic and anoxic rat heart: mechanism and metabolic requirements. Circ Res 60:194-205.
195. Schuldiner S, Shirvan A, and Linial M (1995) Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev 75:369-392.
196. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, and Robertson D (2000) Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 342:541-549.
197. Sharabi Y, Li ST, Dendi R, Holmes C, and Goldstein DS (2003) Neurotransmitter specificity of sympathetic denervation in Parkinson's disease. Neurology 60:1036-1039.
198. Shinkai T, Zhang L, Mathias SA, and Roth GS (1997) Dopamine induces apoptosis in cultured rat striatal neurons; possible mechanism of D2-dopamine receptor neuron loss during aging. J Neurosci Res 47:393-399.
199. Siltanen P, Penttila O, Merikallio E, Kyosola K, Klinge E, and Pispa J (1982) Myocardial catecholamines and their biosynthetic enzymes in various human heart diseases. Acta Med Scand Suppl 660:24-33.
200. Silverstein F and Johnston MV (1984) Effects of hypoxia-ischemia on monoamine metabolism in the immature brain. Ann Neurol 15:342-347.
201. Simonson SG, Zhang J, Canada AT Jr, Su YF, Benveniste H, and Piantadosi CA (1993) Hydrogen peroxide production by monoamine oxidase during ischemia-reperfusion in the rat brain. J Cereb Blood Flow Metab 13:125-134.
202. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, and Quigley EM (1995) Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346:861-864.
203. Sjoerdsma A, King WM, Leeper LC, and Udenfriend S (1957) Demonstration of the 3-methoxy analog of norepinephrine in man. Science (Wash DC) 127:876.
204. Smith AA and Gitlow S (1966) Effect of disulfiram and ethanol on the catabolism of norepinephrine in man., in Biochemical Frontiers in Alcoholism (Maickel RP ed), pp. 53-59, Pergamon, New York.
205. Staal RG and Sonsalla PK (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293:336-342.
206. Stokes AH, Hastings TG, and Vrana KE (1999) Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659-665.
207. Suzuki T, Akaike N, Ueno K, Tanaka Y, and Himori N (1995) MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology 50:357-362.
208. Tabakoff B, Anderson R, and Alivisatos SG (1973) Enzymatic reduction of "biogenic" aldehydes in brain. Mol Pharmacol 9:428-437.
209. Tabakoff B and Erwin VG (1970) Purification and characterization of a reduced nicotinamide adenine dinucleotide phosphate-linked aldehyde reductase from brain. J Biol Chem 245:3263-3268.
210. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, and Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566-573.
211. Tank AW, Weiner H, and Thurman JA (1981) Enzymology and subcellular localization of aldehyde oxidation in rat liver. Oxidation of 3,4-dihydroxyphenylacetaldehyde derived from dopamine to 3,4- dihydroxyphenylacetic acid. Biochem Pharmacol 30:3265-3275.
212. Thiffault C, Langston JW, and Di Monte DA (2002) Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 885:283-288.
213. Tyce GM, Hunter LW, Ward LE, and Rorie DK (1995) Effluxes of 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylglycol and norepinephrine from four blood vessels during basal conditions and during nerve stimulation. J Neurochem 64:833-841.
214. Velez-Pardo C, Jimenez Del Rio M, Verschueren H, Ebinger G, and Vauquelin G (1997) Dopamine and iron induce apoptosis in PC12 cells. Pharmacol Toxicol 80: 76-84.
215. Vlachakis ND, Alexander N, Velasquez MT, and Maronde RF (1979) A radioenzymatic microassay for simultaneous measurement of catecholamines and their deaminated metabolites. Biochem Med 22:323-331.
216. Volles MJ and Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41:4595-4602.
217. Walsh MJ, Truitt EB Jr, and Davis VE (1970) Acetaldehyde mediation in the mechanism of ethanol-induced changes in norepinephrine metabolism. Mol Pharmacol 6:416-424.
218. Weil-Malherbe H and van Buren JM (1969) The excretion of dopamine and dopamine metabolites in Parkinson's disease and the effect of diet thereon. J Lab Clin Med 74:305-318.
219. Weinberger J, Cohen G, and Nieves-Rosa J (1983) Nerve terminal damage in cerebral ischemia: greater susceptibility of catecholamine nerve terminals relative to serotonin nerve terminals. Stroke 14:986-989.
220. Wermuth B and Munch JD (1979) Reduction of biogenic aldehydes by aldehyde reductase and alcohol dehydrogenase from human liver. Biochem Pharmacol 28: 1431-1433.
221. Wolfovitz E, Grossman E, Folio CJ, Reiser HR, Kopin IJ, and Goldstein DS (1993) Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans. Clin Sci 84:549-557.
222. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, and Caron MG (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3:465-471.
223. Yoshimoto K, Komura S, and Kawamura K (1992) Occurrence in vivo of 5-hydroxytryptophol in the brain of rats treated with ethanol. Alcohol Alcoholism 27:131-136.